Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Mason Barge who wrote (247)	11/11/1998 2:29:00 AM
From: Thomas Kirwin	Read Replies (1) \| Respond to of 422

Shareholders Meeting - Q&A Mason, It would be great if your schedule would allow time to visit Immucor's shareholders meeting. I expect that most of the news will be out by the time the meeting starts or shortly thereafter. The questions I have appear below in no particular order of importance: 1) What initiatives have been made to inform the investment community regarding Immucor's tremendous potential now that the FDA has cleared the ABS2000? Specifically, what brokerage houses or investment bankers have been included in any official company presentation? Will their be a road show? Does management see any analyst recommendations in the near future? 2) Does the company have any pro-forma numbers prepared on sales estimates and expected reagent trail? Will the purchase of Gamma be accretive to earnings on an ongoing basis? 3) Given the demands on Mr. Gallup's time would it not be prudent to segregate the roles that he plays, Chairman/CEO/President, into two or three separate positions to better serve the company and shareholders? 4) What has the sales distribution mix of medical instruments been relative to current and new reagent clients? When a current reagent customer purchases an ABS2000 or other device does the reagent trail increase or remain the same? To clarify - I'd really like to know if reagent sales are increasing among old customers who purchase a medical device? How many new reagent centers have purchased devices and what is the expected annual reagent trail in dollars? 5) Is it wise to have so many Immucor Senior Management level individuals on the Board of Directors? 6) What counter measures has the competition implemented that could thwart our hinder Immucor's success? Does the PK80 blood testing system of Olympus America, Inc. constitute a threat? What is DiaMed Ag or Ortho-Clinical Diagnostics up to? 7) Is Immucor still distributing the IMAGN 2000 developed by Biometric Imaging? 8) ReACT questions are; lawsuit developments, automation schedule, distribution or initial sales date, expected sales, reagent trail per ReACT Device, etc. I look forward to any information that you may be able to uncover weather you go to the meeting or not. Regards, Tom